Lazard Asset Management’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.49M | Sell |
78,743
-36,110
| -31% | -$1.14M | ﹤0.01% | 939 |
|
|
2025
Q1 | $3.81M | Buy |
114,853
+105,629
| +1,145% | +$3.5M | 0.01% | 762 |
|
|
2024
Q4 | $316K | Buy |
9,224
+2,541
| +38% | +$87.1K | ﹤0.01% | 1492 |
|
|
2024
Q3 | $266K | Sell |
6,683
-6
| -0.1% | -$239 | ﹤0.01% | 1541 |
|
|
2024
Q2 | $200K | Buy |
6,689
+2,147
| +47% | +$64.2K | ﹤0.01% | 1558 |
|
|
2024
Q1 | $152K | Buy |
4,542
+2,251
| +98% | +$75.3K | ﹤0.01% | 1397 |
|
|
2023
Q4 | $73K | Buy |
2,291
+109
| +5% | +$3.47K | ﹤0.01% | 1784 |
|
|
2023
Q3 | $71K | Buy |
2,182
+427
| +24% | +$13.9K | ﹤0.01% | 1751 |
|
|
2023
Q2 | $61K | Buy |
+1,755
| New | +$61K | ﹤0.01% | 1765 |
|
|
2022
Q3 | – | Sell |
-1,566
| Closed | -$76K | – | 2432 |
|
|
2022
Q2 | $76K | Buy |
+1,566
| New | +$76K | ﹤0.01% | 1619 |
|